The increase in price target from $1 to $8 by a reputable analyst at Morgan Stanley suggests a positive outlook on C4 Therapeutics' stock. This adjustment reflects an expectation of improved performance or valuation, likely leading to increased investor interest and potentially a rise in stock price in the short term.